EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
Geert R. D'Haens 1
Taku Kobayashi 2
Nathan Morris 3
Trevor Lissoos
Amy Hoover
Xingyuan Li
Vipin Arora
Catherine Milch
William Sandborn 4
Bruce E. Sands 5
1 Amsterdam University Medical Centers, Amsterdam, Netherlands
2 Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
3 Eli Lilly and Company, Indianapolis, United States
4 University of California San Diego, La Jolla, United States
5 Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States
Session
IBD (Posters)
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]